-
Mashup Score: 1083Trial of Lixisenatide in Early Parkinson’s Disease | NEJM - 12 day(s) ago
Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson’s disease. In this phase 2, double-bl…
Source: www.nejm.orgCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 1083Trial of Lixisenatide in Early Parkinson’s Disease | NEJM - 12 day(s) ago
Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson’s disease. In this phase 2, double-bl…
Source: www.nejm.orgCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 1081Trial of Lixisenatide in Early Parkinson’s Disease | NEJM - 13 day(s) ago
Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson’s disease. In this phase 2, double-bl…
Source: www.nejm.orgCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 1070Trial of Lixisenatide in Early Parkinson’s Disease | NEJM - 15 day(s) ago
Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson’s disease. In this phase 2, double-bl…
Source: www.nejm.orgCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 1065Trial of Lixisenatide in Early Parkinson’s Disease | NEJM - 16 day(s) ago
Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson’s disease. In this phase 2, double-bl…
Source: www.nejm.orgCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 1062Trial of Lixisenatide in Early Parkinson’s Disease | NEJM - 16 day(s) ago
Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson’s disease. In this phase 2, double-bl…
Source: www.nejm.orgCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 1062Trial of Lixisenatide in Early Parkinson’s Disease | NEJM - 16 day(s) ago
Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson’s disease. In this phase 2, double-bl…
Source: www.nejm.orgCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 1062Trial of Lixisenatide in Early Parkinson’s Disease | NEJM - 16 day(s) ago
Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson’s disease. In this phase 2, double-bl…
Source: www.nejm.orgCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 1054Trial of Lixisenatide in Early Parkinson’s Disease | NEJM - 16 day(s) ago
Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson’s disease. In this phase 2, double-bl…
Source: www.nejm.orgCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 1054Trial of Lixisenatide in Early Parkinson’s Disease | NEJM - 17 day(s) ago
Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson’s disease. In this phase 2, double-bl…
Source: www.nejm.orgCategories: General Medicine News, Expert PicksTweet
Some exciting new GLP-1 drug randomized trial evidence for *potential* disease-modifying impact on #Parkinsons disease (there are none). No progression of motor disability in the Rx group for 12 months. https://t.co/FCNjfIiZT5 https://t.co/NPusWtLXRO